Results 231 to 240 of about 31,098,092 (376)
Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal +16 morewiley +1 more sourceWhole genome sequence analysis of low-density lipoprotein cholesterol across 246 K individuals. [PDF]
Genome BiolSelvaraj MS, Li X, Li Z, Van Buren E, Haidermota S, Postupaka D, Hornsby W, Bis JC, Brody JA, Cade BE, Chung RH, Curran JE, Damrauer SM, de Las Fuentes L, de Vries PS, Duggirala R, Freedman BI, Graff M, Guo X, Hidalgo BA, Hou L, Irvin R, Judy R, Kalyani RR, Kelly TN, Konigsberg IR, Kral BG, Kwee LC, Levy D, Li C, Manichaikul AW, Martin LW, Montasser ME, Morrison AC, Naseri T, North KE, O'Connell JR, Palmer ND, Peyser PA, Reiner AP, Shah SH, Smit RAJ, Smith JA, Taylor KD, Tiwari H, Tsai MY, Viali S, Wang Z, Wang Y, Zhao W, Arnett DK, Blangero J, Boerwinkle E, Bowden DW, Carlson JC, Chen YI, Ellinor PT, Fornage M, He J, Heard-Costa N, Kaplan RC, Kardia SLR, Kooperberg C, Kraus WE, Lange LA, Loos RJF, Mitchell BD, Psaty BM, Rader DJ, Redline S, Rich SS, Yanek LR, Gibbs R, Gabriel S, Viaud-Martinez KA, Dutcher SK, Germer S, Kim R, Rotter JI, Lin X, Peloso GM, NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Natarajan P. +82 moreeuropepmc +1 more sourceEffective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more sourceExploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair +17 morewiley +1 more sourceSequence analysis of two F1 mycobacteriophages, Deb65 and DocMcStuffins. [PDF]
Microbiol Resour AnnouncRoyster MO, Figgins V, Pande V, Robinson JD, Abdi DS, Amin A, Ansah Z, Bomersheim EW, Dunn G, Elfaki AA, Foulk J, Ingle KC, Lavu AD, Pande V, Shan PT, Smithbey MP, Ternstrom GR, Trager OS, Washington DA, Xu M, Saha MS. +20 moreeuropepmc +1 more source